2020
Impaired Hematological Status Increases the Risk of Mortality among HIV-Infected Adults Initiating Antiretroviral Therapy in Tanzania
Noor RA, Abioye AI, Hertzmark E, Darling AM, Aboud S, Mugusi FM, Sudfeld CR, Spiegelman D, Fawzi WW. Impaired Hematological Status Increases the Risk of Mortality among HIV-Infected Adults Initiating Antiretroviral Therapy in Tanzania. Journal Of Nutrition 2020, 150: 2375-2382. PMID: 32621487, PMCID: PMC7540061, DOI: 10.1093/jn/nxaa172.Peer-Reviewed Original ResearchConceptsRisk of mortalityPrevalence of anemiaHAART initiationHematological statusIron deficiencyAntiretroviral therapySerum ferritinSevere anemiaIncident clinical outcomesRelation of anemiaTrial of multivitaminsActive antiretroviral therapyHIV disease progressionCase-cohort studyIron deficiency anemiaProportional hazards modelElevated ironNonanemic participantsHIV patientsMultivariate adjustmentClinical outcomesMorbidity outcomesAnemia etiologyDeficiency anemiaIron supplementation
2005
Insulin Resistance in HIV-Infected Men and Women in the Nutrition for Healthy Living Cohort
Jones CY, Wilson IB, Greenberg AS, Shevitz A, Knox TA, Gorbach SL, Spiegelman D, Jacobson DL, Wanke C. Insulin Resistance in HIV-Infected Men and Women in the Nutrition for Healthy Living Cohort. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 40: 202-211. PMID: 16186739, DOI: 10.1097/01.qai.0000165910.89462.2f.Peer-Reviewed Original ResearchConceptsQuantitative insulin sensitivity check indexWorse insulin resistancePrevalence of IRInsulin resistanceNHANES IIIHigher high-density lipoproteinInsulin sensitivity check indexNutrition Examination Survey IIIHealthy Living cohortHealthy Living StudyHIV-Infected MenMore insulin resistanceActive antiretroviral therapyCD4 cell countCross-sectional study designInjection drug useLess insulin resistanceExamination Survey IIINHANES III participantsGreater waist circumferenceHigh-density lipoproteinLow-density lipoproteinProtease inhibitorsLiving cohortPI-HAARTIncreasing Risk of 5% or Greater Unintentional Weight Loss in a Cohort of HIV-Infected Patients, 1995 to 2003
Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke C. Increasing Risk of 5% or Greater Unintentional Weight Loss in a Cohort of HIV-Infected Patients, 1995 to 2003. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 40: 70-76. PMID: 16123685, DOI: 10.1097/01.qai.0000159627.54149.2e.Peer-Reviewed Original ResearchConceptsCohort of HIVUnintentional weight lossWeight lossAntiretroviral therapyBody compositionLow CD4 cell countsHigher HIV viral loadHigher body mass indexCare of HIVHealthy Living cohortActive antiretroviral therapyCD4 cell countCombination antiretroviral therapyHIV viral loadBody mass indexRisk of deathPresence of diarrheaFederal poverty levelLiving cohortHIV infectionMass indexMost AIDSOpportunistic infectionsViral loadPatient populationPrevalence of, Evolution of, and Risk Factors for Fat Atrophy and Fat Deposition in a Cohort of HIV-Infected Men and Women
Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, Evolution of, and Risk Factors for Fat Atrophy and Fat Deposition in a Cohort of HIV-Infected Men and Women. Clinical Infectious Diseases 2005, 40: 1837-1845. PMID: 15909274, DOI: 10.1086/430379.Peer-Reviewed Original ResearchConceptsFat atrophyRisk factorsFat depositionBaseline prevalenceCentral fat depositionHIV-Infected MenActive antiretroviral therapyHigh triglyceride levelsHuman immunodeficiency virusNutrition Examination SurveyPercent of subjectsSkin-fold measurementsBody fat levelsAbacavir useHIV loadStavudine useAntiretroviral therapyHip ratioImmunodeficiency virusExamination SurveyTriglyceride levelsNational HealthHigh school educationSmaller hipIndependent syndrome
2004
Understanding the Role of HIV Load in Determining Weight Change in the Era of Highly Active Antiretroviral Therapy
Mwamburi DM, Wilson IB, Jacobson DL, Spiegelman D, Gorbach SL, Knox TA, Wanke CA. Understanding the Role of HIV Load in Determining Weight Change in the Era of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases 2004, 40: 167-173. PMID: 15614708, DOI: 10.1086/426591.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyVirus loadBody weightAntiretroviral therapyHIV infectionWeight changeStudy visitHuman immunodeficiency virus RNA loadHighly Active Antiretroviral TherapyAbsence of HAARTProspective cohort studyCell count decreaseVirus RNA loadTime of enrollmentStudy intervalRepeated-measures analysisHIV loadHAART useCohort studyRNA loadHAARTPatientsEligible sampleCell countCount decrease
2003
Difficulty Swallowing and Lack of Receipt of Highly Active Antiretroviral Therapy Predict Acute Weight Loss in Human Immunodeficiency Virus Disease
Jacobson DL, Bica I, Knox TA, Wanke C, Tchetgen E, Spiegelman D, Silva M, Gorbach S, Wilson IB. Difficulty Swallowing and Lack of Receipt of Highly Active Antiretroviral Therapy Predict Acute Weight Loss in Human Immunodeficiency Virus Disease. Clinical Infectious Diseases 2003, 37: 1349-1356. PMID: 14583869, DOI: 10.1086/379072.Peer-Reviewed Original ResearchConceptsAcute weight lossHuman immunodeficiency virus (HIV) diseaseOral symptomsWeight lossLack of receiptActive antiretroviral therapyUpper respiratory symptomsVirus diseaseTrouble swallowingAbdominal painAntiretroviral therapyRespiratory symptomsDifficulty swallowingNutrient malabsorptionSkin symptomsCommon symptomsRecent symptomsCaloric intakeSymptom complexSymptomsWeight changeDiarrheaMetabolic needsSwallowingDiseaseUse of Complementary and Alternative Therapies by Patients With Human Immunodeficiency Virus Disease in the Era of Highly Active Antiretroviral Therapy
Bica I, Tang AM, Skinner S, Spiegelman D, Knox T, Gorbach S, Wilson IB. Use of Complementary and Alternative Therapies by Patients With Human Immunodeficiency Virus Disease in the Era of Highly Active Antiretroviral Therapy. Journal Of Alternative And Complementary Medicine 2003, 9: 65-76. PMID: 12676036, DOI: 10.1089/107555303321222955.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusActive antiretroviral therapyCAM useAntiretroviral therapyHighly Active Antiretroviral TherapyHuman immunodeficiency virus (HIV) diseaseCAM therapy useHealthy Living StudyPotential drug interactionsUse of ComplementaryLow-risk groupAlternative medical therapiesEffective drug treatmentCross-sectional analysisLeast high schoolHAART useCohort studyMale patientsMedical therapyTherapy useImmunodeficiency virusComplementary therapiesAlternative therapiesStudy visitRisk groups
2002
Weight Loss and Survival in HIV-Positive Patients in the Era of Highly Active Antiretroviral Therapy
Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight Loss and Survival in HIV-Positive Patients in the Era of Highly Active Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2002, 31: 230-236. PMID: 12394802, DOI: 10.1097/01.qai.0000026514.98625.8f.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyWeight lossAntiretroviral therapyHAART useIndependent predictorsPrevious visitHighly Active Antiretroviral TherapyHealthy Living StudyCD4 cell countHIV-positive patientsHIV-positive participantsBody mass indexStrong independent predictorFurther prognostic valueProportional hazards modelBioelectrical impedance analysisFour- to sixfold increaseImportant comorbidityMass indexPrognostic valuePotential confoundersRelative riskStudy populationLiving StudyHazards modelRole of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men
Roubenoff R, Grinspoon S, Skolnik PR, Tchetgen E, Abad L, Spiegelman D, Knox T, Gorbach S. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. AJP Endocrinology And Metabolism 2002, 283: e138-e145. PMID: 12067854, DOI: 10.1152/ajpendo.00426.2001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntiretroviral Therapy, Highly ActiveBody CompositionBody WeightCD4 Lymphocyte CountCytokinesEnergy MetabolismFollow-Up StudiesHIV InfectionsHIV Wasting SyndromeHumansInterleukin-1Linear ModelsLongitudinal StudiesMaleMiddle AgedNutritional StatusRestTestosteroneThinnessTumor Necrosis Factor-alphaViral LoadConceptsLBM lossPeripheral blood mononuclear cellsIL-1 beta productionWeight lossActive antiretroviral therapyCohort of patientsSerum free testosteroneBlood mononuclear cellsInadequate dietary intakeOngoing cohort studyCytokine tumor necrosisRole of cytokinesIL-1 betaTNF-alpha productionInterleukin-1 betaMo of observationLean body massKcal/dayAntiretroviral therapyCohort studyFree testosteroneHIV infectionIndependent predictorsCytokine productionMononuclear cells
1999
Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy
Shevitz A, Knox T, Spiegelman D, Roubenoff R, Gorbach S, Skolnik P. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 1999, 13: 1351-1357. PMID: 10449288, DOI: 10.1097/00002030-199907300-00012.Peer-Reviewed Original ResearchConceptsFat-free massActive antiretroviral therapyHAART useHIV RNAAntiretroviral therapyCohort studyViral burdenKJ/dayHIV-seropositive menCD4 cell countHIV-seropositive personsLog10 copies/Energy expenditureLarge cohort studyIndependent effectsCross-sectional analysisHIV diseaseMedication regimensViral loadCopies/Adjusted REECell countElevated REEViral replicationHAART
1998
The effect of protease inhibitors on weight and body composition in HIV-infected patients
Silva M, Skolnik P, Gorbach S, Spiegelman D, Wilson I, Fernández-DiFranco M, Knox T. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998, 12: 1645-1651. PMID: 9764784, DOI: 10.1097/00002030-199813000-00012.Peer-Reviewed Original ResearchConceptsLean body massPI therapyHIV infectionWeight gainViral loadPhysical functioningHealth perceptionBody compositionCurrent health perceptionsActive antiretroviral therapyPI treatmentProtease inhibitor therapyBody mass indexGreater weight gainHuman growth hormoneAntiretroviral therapyHIV cohortBody massInhibitor therapyMass indexOptimal therapyFat massAnabolic stimuliPatientsGrowth hormone